Acumen pharmaceuticals to participate in the h.c. wainwright 26th annual global investor conference

Newton, mass., sept. 03, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in a fireside chat at the h.c. wainwright 26th annual global investor conference on tuesday, sept. 10, 2024, at 1:30 p.m. et.
ABOS Ratings Summary
ABOS Quant Ranking